CN101332199A - Anticancer composition containing phosphoinositide 3-kinase inhibitor and topology enzyme inhibitor - Google Patents
Anticancer composition containing phosphoinositide 3-kinase inhibitor and topology enzyme inhibitor Download PDFInfo
- Publication number
- CN101332199A CN101332199A CNA200810303544XA CN200810303544A CN101332199A CN 101332199 A CN101332199 A CN 101332199A CN A200810303544X A CNA200810303544X A CN A200810303544XA CN 200810303544 A CN200810303544 A CN 200810303544A CN 101332199 A CN101332199 A CN 101332199A
- Authority
- CN
- China
- Prior art keywords
- eop
- release
- sustained
- injection
- slow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An anti-cancer combination containing a phosphoinositide3-kinase inhibitor (PI3Ki) and/or a topoisomerase inhibitor is a sustained-release injection, which contains a sustained-release microsphere and a menstruum. The sustained-release microsphere contains PI3Ki and/or topoisomerase inhibitor and sustained-release auxiliary materials; the menstruum is an ordinary menstruum or a special menstruum containing a suspending agent. The viscosity of the suspending agent is 100cp to 3000cp (at the temperature of 20 DEG to 30 DEG) and the suspending agent is selected from carboxymethylcellulose sodium, etc. The sustained-release auxiliary materials are selected from a polyphosphonate copolymer of p(LAEG-EOP), p(DAPG-EOP), p(BHET-EOP/TC), p(BHET-EOP/TC ), p(BHDPT-EOP/TC), p(BHDPT-EOP/TC), p(CHDM-HOP) or p(CHDM-EOP), and the like, or a copolymer of polyphosphate ester and polylactic acid, polifeprosan, dienoic fatty acid or decanedioic acid, a copolymer or a mixture of p(erucic acid dimer-decanedioic acid) or a copolymer or a mixture of p(boletic acid-decanedioic acid). The anti-cancer combination is also made into a sustained-release implanting agent, which can be injected or placed in or around tumor to maintain the effective medicine density for more than 40 days. The anti-cancer combination can also obviously reduce the general reaction of the medicine and selectively enhance the curing effect of non-operational therapies such as radiotherapy and chemotherapy.
Description
(1) technical field
The present invention relates to the anti-cancer composition of a kind of including phosphatidylinositol3 3-kinase inhibitor and/or topoenzyme inhibitor,, belong to technical field of pharmaceuticals for slow-releasing anticarcinogen injection and sustained-release implant.
(2) background technology
As class chemotherapeutics commonly used, phosphoinositide 3-kinase inhibitor has been widely used in the treatment of multiple malignant tumor, and action effect is comparatively obvious.Yet its significant toxic reaction has greatly limited the extensive use of such medicine.
Because entity tumor excessive expansion hypertrophy, the viscosity of matter was high than its normal surrounding tissue all between matter pressure, tissue elasticity pressure, fluid pressure reached therebetween, and therefore, conventional chemotherapy is difficult to tumor by local and forms effective drug level.In addition, blood vessel in the mesenchyma stroma of tumors, connective tissue, stromatin, fibrin and collagen protein etc. not only provide support and requisite nutrient substance for the growth of tumor cell, also influenced chemotherapeutics around tumor and the infiltration in the tumor tissues and diffusion (carry and to wait " situation of extracellular matrix to entity tumor in the medicine influence of turning round " " cancer research " 60 phase 2497-503 page or leaf (2000) (Netti PA referring to the Buddhist nun, Cancer Res.2000,60 (9): 2497-503)).So, improve the restriction that dosage is subjected to general reaction again merely.Pharmaceutical topical application may solve the problem of drug level to a certain extent, yet operation techniques such as medicine implantation are complicated, traumatic big, the various complication such as, infection hemorrhage, immunity reduction, also can cause or quicken the diffusion and the transfer of tumor except that easily causing.In addition, the preparation of perioperatively itself and expensive expense usually influence its effective enforcement.
In addition, the DNA repair function in many tumor cells obviously increases after chemotherapy.The latter often causes the enhancing of tumor cell to the toleration of cancer therapy drug, consequently treatment failure.In addition, the cancer drug therapy of low dosage not only can increase the Drug tolerance of cancerous cell, but also can promote its infiltrative growth " (referring to beam etc. " increased the Drug tolerance of human lung carcinoma cell and external wetting capacity after the cancer therapy drug pulse screening and with the change of gene expression " " international journal of cancer " 111 phase 484-93 page or leaf (2004) (Liang Y; et al., Int J Cancer.2004; 111 (4): 484-93)).
Therefore, study both handled easilies, can keep high drug level at tumor by local can increase tumor cell again the preparation of the sensitivity of medicine and method are just become when previous important topic.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, the anticancer pharmaceutical composition of a kind of including phosphatidylinositol3 3-kinase inhibitor and topoenzyme inhibitor is provided, particularly, be the slow-releasing anticarcinogen injection or the sustained-release implant of a kind of including phosphatidylinositol3 3-kinase inhibitor and topoenzyme inhibitor.
Phosphoinositide 3-kinase inhibitor has been widely used in the multiple entity tumor of treatment both at home and abroad as the new cancer therapy drug of a class.Yet in application process, its tangible general toxicity has greatly limited the application of this medicine.
Be effectively to improve tumor by local drug level, reduce the drug level of medicine in blood circulation, people have studied the drug sustained release system of including phosphatidylinositol3 3-kinase inhibitor, comprise that magnetic microsphere (sees: China Patent No. CN200410044113.8; CN200410009233.4), sustained-release micro-spheres (capsule) (see: China Patent No. CN200410023746.0) and nanoparticle (see: China Patent No. CN200410099292.5; CN200510002387.5) etc.Yet, solid sustained-release implant (China Patent No. ZL96115937.5; ZL97107076.8; CN200410084621.9), miniature implantation device (China Patent No. CN200510011250.6), sustained-release micro-spheres (the China Patent No. ZL00809160.9 of band radioactive source; U.S. Pat 5,651,986) all there are the problems such as operation, weak curative effect, complication be many that are not easy.In addition, the sensitivity that many entity tumors are drawn together phosphoinositide 3-kinase inhibitor to anticancer medicated bag is relatively poor, and is easy to generate drug resistance in therapeutic process.
The present invention finds that topoenzyme inhibitor and phosphoinositide 3-kinase inhibitor share its antitumaous effect is strengthened mutually; In addition, the combination of phosphoinositide 3-kinase inhibitor and topoenzyme inhibitor is made drug level that anticancer medicine slow-release preparation containing (being mainly slow releasing injection and sustained-release implant) not only can greatly improve tumor by local, reduces the drug level of medicine in blood circulation, is reduced the toxicity of medicine to normal structure, can also greatly make things convenient for the medicine injection, reduce operation technique complication, reduce patient's expense.The above unexpected main contents of the present invention of finding to constitute.
The present invention also finds, with regard to composition such as phosphoinositide 3-kinase inhibitor and topoenzyme inhibitor with active anticancer, is not the slow release effect that all slow-release auxiliary material all can reach effective release.Pharmaceutic adjuvant have hundreds of more than, pharmaceutic adjuvant with slow releasing function, particularly the pharmaceutic adjuvant that different pharmaceutical slowly can be discharged in the regular hour in human body or animal body must could obtain through a large amount of creationary experiments, specific slow-release auxiliary material and can need be passed through a large amount of creative works by the selection of the combination of slow releasing pharmaceutical and could determine.Discharged and be not enough to obtain active drug concentration slowly, thereby effective kill tumor cell; Cause prominent releasing if discharge too fast meeting, then cause general toxic reaction easily, as polifeprosan (A.J.Domb etc., Biomaterials (1995), 16 (14): 1069-1072; Wenbin Dang etc., Journal ofControlled Release (1996), 42:83-92; Eric P.Sipos etc., Cancer ChemotherPharmacol (1997), 39:383-389; Lawrence K.Fung etc., Cancer Research (1998), 58:672-684).The data of release characteristics need could obtain through a large amount of creationary experiments in inside and outside in the related data, particularly animal body, are not just can determine to have unobviousness through limited experiment.
The present invention finds, poly-phosphide (polyphosphoesters), poly phosphate (polyphosphate), poly-phosphite ester (polyphosphite), polyphosphonates (polyphosphonate), polyester cyclic phosphate (poly (cycloaliphatic phosphoester)), etherophosphoric acid phosphate ester high molecular polymers such as (EOP) can steadily slowly discharge effective ingredient of the present invention, and deenergized period is more than 40 to 100 days.And do not have prominent releasing, particularly mix or copolymerization with sugared acid anhydride family macromolecule such as polylactic acid.The prominent deficiency of releasing with too fast release of more than finding to have solved existing slow releasing preparation is slowly more than release 40-100 days.More than find to constitute principal character of the present invention.
A kind of form of phosphoinositide 3-kinase inhibitor slow releasing agent of the present invention is a slow releasing injection, is made up of sustained-release micro-spheres and solvent.Particularly, this slow-releasing anticarcinogen injection is grouped into by following one-tenth:
(A) sustained-release micro-spheres comprises:
Anticancer effective component 0.5-70%
Slow-release auxiliary material 30-99%
Suspending agent 0.0-30%
More than be weight percentage
With
(B) solvent is for common solvent or contain the special solvent of suspending agent.
Wherein,
Anticancer effective component is phosphoinositide 3-kinase inhibitor and/or topoenzyme inhibitor.
Phosphoinositide 3-kinase (phosphoinositide 3-kinase, abbreviation PI3K) inhibitor (PI3Ki) is selected from 7-hydroxy-star shaped spore native (7-hydroxyl-staurosporine, UCN-01), 7-O-alkyl-star shaped spore native (UCN-02), the beta-methoxy-star shaped spore native, alkyl phosphate choline (alkylphosphocholines), hexa-decyl choline phosphate (hexadecylphosphocholine, MIL, HPC, Miltefosine), octadecyl-(1, the 1-dimethyl-4-piperidine) (Octadecyl-(1 for phosphate, 1-dimethyl-4-piperidylio) phosphate, perifosine, D-21266), 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine (AMG-PC, 1-O-hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine, ET-16-OCH3), 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine (1-O-Octadecyl-2-O-methyl-rac-glycerophosphocholine, ET-18-OCH3, edelfosine), 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine (1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine, ilmofosine, L-ET-18-OCH (3)), inositolpolyphosphates (inositolpolyphosphates), cyclosporin A (Cyclosporin A), basic phosphocholine (the Tetradecylphosphocholine of 14 (alkane), TPC), six decyl phosphoric acid (N-N-N-trimethyl) hexanol amine (hexadecylphospho (N-N-N-trimethyl) hexanolamine, HPC6), D 19391 (octadecylphosphocholine, OPC) or octadecyl-[2-(N-methyl piperidine) ethyl]-phosphate (octadecyl-[2-(N-methylpiperidinio) ethyl]-phosphate, D-20133 or OMPEP).
With 7-hydroxy-star shaped spore native, 7-O-alkyl-star shaped spore native, the beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate (Miltefosine), octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate (perifosine), 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine (edelfosine), 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine (ilmofosine), inositolpolyphosphates, cyclosporin A, the basic phosphocholine of 14 (alkane), six decyl phosphoric acid (N-N-N-trimethyl) hexanol amine, D 19391 or octadecyl-[2-(N-methyl piperidine) ethyl]-phosphate is preferred.
The content of phosphoinositide 3-kinase inhibitor in compositions is 0.01%-60%, is good with 1%-40%, is best with 2%-30%, more than all be weight percentage.
Topoenzyme inhibitor is selected from one of following or combination: Camptothecin (camptothecin, CPT), the derivant of Camptothecin, lurtotecan (Lurtotecan), topotecan (10-hydroxy-9-dimethylaminomethyl-(S)-camptothecin, topotecan), irinotecan (irinotecan, IRT), 9-nitro Camptothecin (9-nitrocamptothecin, 9NC), 7-ethyl-10-hydroxyl-Camptothecin (7-ethyl-10-hydroxy-camptothecin, SN-38), 7-ethyl-10-[4-(1-piperidino)-1-piperidino] and the carbonyl Camptothecin (7-ethyl-10-[4-(1-pyperidino)-1-piperidino] carbonyloxycamptothecin, CPT-11), 10-hydroxyl-Camptothecin (10-Hydroxycamptothecin, HCPT), Homocamptothecins (Homocamptothecins), MD-CPT (10,11-methylenedioxy, MD-CPT), (RS)-MD-CPT (10,11-MD-20 (RS)-CPT), (S)-MD-CPT glycinate (10,11-MD-20 (S)-cpT-glycinate ester (Gly) .HCl), 9-amino-(S)-MD-CPT glycinate (9-amino-10,11-MD-20 (S)-CPT-Gly), N-[2-(dimethylamino) ethyl] and pyridine-4-carboxylic acid amides (N-[2-(dimethylamino) ethyl] acridine-4-carboxamide, DACA) and the derivant of 5 or 7 replacements, podophyllotoxin (podophyllotoxin), etoposide (Etoposide, epipodophyllotoxins, etoposide, etoposide, VP-16), teniposide (Teniposide, teniposide, VM-26), Podophyllinic acid, podophyllotoxin, trihydroxy-isoflavone (Genistein), the 14-doxorubicin, amrubicin (Amrubicin), Ai Rou is than star (4 '-(acridinylamino) methansulfon-m-anisidide (amsacrine, m-AMSA)), the nor-oxygen daunorubicin of 4-(4-demeth oxydaunorubicin), detorubicin, amycin, epirubicin, 7-O-methyl Nuo Jia-4 ' epirubicin (7-o-methylnogallol-4 '-epiadriamycin), esorubicin (Esorubicin), carubicin, idarubicin (idarubicin, IDA), rodorubicin, leurubicin (Leurubicin), medorubicin, Nemorubicin (Nemorubicin), doxorubicin, pirarubicin, valrubicin (N-trifluoro toxin-14-valerate, N-trifluoroacetyladriamycin-14-valerate, AD 32, valrubicin), 2-[4-(7-chloro-2-quinoxalinyl phenoxy base]-propanoic acid ((2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid, XK469), zorubicin (Zorubicin), N-(2-ethyl chloride)-N-nitroso-group urea groups daunorubicin (N-(2-Chloroethyl)-N-nitrosoureidodaunorubicin, AD 312), pyrazoles [1,5-a] indole derivatives, as, but be not limited to, GS-2,-3,-4, GS-5; The dioxy piperazine oxazine derivatives, as, but be not limited to, (+)-1, two (3, the 5-dioxo piperazinyl) propane ((+)-1 of 2-, 2-bis (3,5-dioxopiperazinyl-1-yl) propane, ICRF-187) ,-2,3-two (3,5-dioxo piperazine-1-yl) butane (meso-2,3-bis (3,5-dioxopiperazine-1-yl) butane, ICRF-193), two dioxo piperazine (bisdioxopiperazine); Suramin (Suramin), deoxyguanosine (Deoxyguanosine), lithocholic acid (lithocholic acid, LCA) or Hydrazoic acid,sodium salt (sodium azide).
In the above topology enzyme inhibitor, serve as preferred than star, detorubicin, amycin, epirubicin, esorubicin, carubicin, rodorubicin, leurubicin, medorubicin, Nemorubicin, zorubicin, doxorubicin, pirarubicin, valrubicin or idarubicin with Camptothecin, hydroxy-camptothecin alkali, lurtotecan, topotecan, irinotecan, etoposide, teniposide, amrubicin, Ai Rou.Topoenzyme inhibitor shared ratio in compositions is decided because of concrete condition, generally speaking, can be good with 1%-40% from 0.01%-50%, is best with 5%-30%.All be weight percentage.
The percentage by weight of antitumor drug in medicament slow-release microsphere is 0.5%-60%, is good with 2%-40%, is best with 5%-30%.When use in conjunction, the weight ratio of phosphoinositide 3-kinase inhibitor and topoenzyme inhibitor is 1-9: 1 to 1: 1-9, with 1-4: 1 and 4-1: 1 serves as preferred, 1-2: 1 and 2-1: 1 for most preferably.
Anticancer effective component in the slow-releasing anticarcinogen injection microsphere of the present invention is preferably as follows, and all is weight percentage:
(a) 7-hydroxy-star shaped spore native of 1-40%, 7-O-alkyl-star shaped spore native, beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate, octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate, 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine or 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine;
(b) Camptothecin of 1-40%, hydroxy-camptothecin alkali, lurtotecan, topotecan, irinotecan, etoposide, teniposide, amrubicin, Ai Rou are than star, detorubicin, amycin, epirubicin, esorubicin, carubicin, rodorubicin, leurubicin, medorubicin, Nemorubicin, zorubicin, doxorubicin, pirarubicin, valrubicin or idarubicin; Or
(c) 7-hydroxy-star shaped spore native of 1-40%, 7-O-alkyl-star shaped spore native, the beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate, octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate, 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, the Camptothecin of 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine or 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine and 1-40%, hydroxy-camptothecin alkali, lurtotecan, topotecan, irinotecan, etoposide, teniposide, amrubicin, Ai Rou compares star, detorubicin, amycin, epirubicin, esorubicin, carubicin, rodorubicin, leurubicin, medorubicin, Nemorubicin, zorubicin, doxorubicin, pirarubicin, the combination of valrubicin or idarubicin.
Slow-release auxiliary material range of viscosities IV (dl/g) 0.05～1.8 serves as preferred with 0.1～1.4, with 0.1～1.4 for most preferably.The used slow-release auxiliary material of the present invention is selected from poly-phosphide (polyphosphoesters), poly phosphate (polyphosphate), poly-phosphite ester (polyphosphite), polyphosphonates (polyphosphonate), polyester cyclic phosphate (poly (cycloaliphatic phosphoester)), etherophosphoric acid (EOP), poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-etherophosphoric acid/terephthalic acids ester hydrochloride ester, 80/20) (p (BHET-EOP/TC, 80/20)), p (BHET-EOP/TC, 50/50), poly-(L-lactide-co-etherophosphoric acid (p (LAEG-EOP)), poly-(L-lactide-co-phosphoric acid propyl ester) (p (DAPG-EOP)), anti-(formula)-1,4-dimethyl cyclohexane (trans-1,4-cyclohexanedimethanil, CHDM), hexyl dichloro-phosphate ester (hexyl phosphorodichloridate, HOP), 4-dimethylamino pyridine (4-dimethylaminopyridine, DMAP), poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-4-dimethylamino pyridine-co-etherophosphoric acid/terephthalic acids ester hydrochloride, 80/20) (p (BHDPT-EOP/TC, 80/20)), p (BHDPT-EOP/TC, 50/50), poly-(anti-(formula)-1,4-dimethyl cyclohexane-etherophosphoric acid) (p (CHDM-HOP)), poly-(anti-(formula)-1, a kind of or its combination in the 4-dimethyl cyclohexane-hexyl dichloro-phosphate ester (p (CHDM-EOP)).
Serve as preferred with p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP), p (CHDM-EOP) in the above-mentioned phosphate ester.
The used slow-release auxiliary material of the present invention also is selected from above-mentioned phosphate ester and poly-dl-lactide (D, L-PLA), poly-dl-lactide/ethanol copolymer (D, L-PLGA), monomethyl polyethylene glycol (MPEG-PLA), monomethyl polyethylene glycol copolymer (MPEG-PLGA), polyethylene glycol (PLA-PEG-PLA), polyethylene glycol copolymer (PLGA-PEG-PLGA), end carboxyl polylactic acid (PLA-COOH), end carboxyl polylactic acid/ethanol copolymer (PLGA-COOH), polifeprosan, bis-fatty acid and decanedioic acid copolymer (PFAD-SA), poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)], poly-(fumaric acid-decanedioic acid) [P (FA-SA)], ethylene vinyl acetate copolymer (EVAc), polylactic acid (PLA), the copolymer of polyglycolic acid and hydroxyacetic acid (PLGA), poly-to dioxy cyclohexanone (PDO), PTMC (PTMC), xylitol, oligosaccharide, chrondroitin, chitin, chitosan, poloxamer 188, poloxamer 407, hyaluronic acid, collagen protein, the blend of gelatin or albumin glue or copolymer.Wherein the shared percentage by weight of phosphate ester is 1-99%, is preferred with 40-80%, and 50-60% is for most preferably.
Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
For regulating drug releasing rate or changing other characteristic of the present invention, can change the composition and the proportioning of monomer component or molecular weight, interpolation or the adjusting pharmaceutic adjuvant of polymer, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar or salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide, (sulphuric acid) chrondroitin and chitin etc., and wherein salt can be, but is not limited to, potassium salt and sodium salt etc.
Except that above-mentioned adjuvant, also can select for use other materials to see United States Patent (USP) (4757128; 4857311; 4888176; 4789724) and in " pharmaceutic adjuvant complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor) have a detailed description.In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some pharmaceutic adjuvant, comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or blocker etc.
The content of suspending agent is decided because of the medicine that solvent suspended, composition, character and the requirement thereof of sustained-release micro-spheres (or microcapsule), the preparation method of injection and the kind and the composition thereof of suspending agent, as, sodium carboxymethyl cellulose can be 0.5-5%, but with 1-3% is preferred, mannitol and/or sorbitol are 5-30%, but is preferred with 10-20%, and polysorbas20, polysorbate40 or Tween 80 are 0.05-2%, but are preferred with 0.10-0.5%.In most cases, sustained-release microparticle is made up of effective ingredient and slow-release auxiliary material, and solvent is special solvent.When solvent was common solvent, medicine that is suspended or sustained-release micro-spheres (or microcapsule) then were made up of effective ingredient, slow-release auxiliary material and/or suspending agent.In other words, when the suspending agent in the sustained-release microparticle (A) was " 0 ", solvent (B) was special solvent, and when the suspending agent in the sustained-release microparticle (A) was not " 0 ", solvent (B) can be common solvent or special solvent.The viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), preferred 1000cp-3000cp (20 ℃-30 ℃ time), most preferably 1500cp-3000cp (20 ℃-30 ℃ time).
Common solvent can be, but is not limited to, the buffer that distilled water, water for injection, physiology are prepared towards liquid, dehydrated alcohol or various salt, and pharmacopeia has respective specified; The special solvent of indication of the present invention is the common solvent that contains suspending agent, suspending agent can be, but be not limited to one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, polysorbas20, polysorbate40 and Tween 80 or its combination.The content of suspending agent is 0.1-30% volume weight percentage ratio in the special solvent, is preferably as follows:
(a) 0.5-5% sodium carboxymethyl cellulose; Or
(b) 0.5-5% sodium carboxymethyl cellulose and 0.1-0.5% Tween 80; Or
(c) 5-20% mannitol; Or
(d) 5-20% mannitol and 0.1-0.5% Tween 80; Or.
(e) 0.5-5% sodium carboxymethyl cellulose, 5-20% sorbitol and 0.1-0.5% Tween 80.
The above-mentioned volume weight percentage ratio that is contains the weight of suspending agent in the common solvent of unit volume, as g/ml, kg/L down with.
The preparation of injection comprises that the preparation of preparation, solvent of sustained-release micro-spheres or drug microparticles and sustained-release micro-spheres or drug microparticles suspend, and make injection at last in solvent.
Wherein, sustained-release micro-spheres or drug microparticles can prepare with some kinds of methods: as, but be not limited to, mixing method, fusion method, dissolution method, spray drying method for preparation microsphere, dissolution method are in conjunction with freezing (drying) comminuting method, liposome bag medicine method and emulsion process etc.Serve as preferred wherein with dissolution method (being the solvent volatility process), freezing (drying) comminuting method, seasoning, spray drying method and emulsion process.Microsphere then can be used for preparing above-mentioned various slow releasing injection.The particle diameter of suspended drug or sustained-release micro-spheres (or microcapsule) decide because of specifically needing, and can be, but be not limited to, 1-300um, but be that preferably 30-150um most preferably with 20-200um.Medicine or sustained-release micro-spheres can be made into microsphere, sub-micro ball, microemulsion, nanosphere, granule or spherical piller.Slow-release auxiliary material is above-mentioned bio-capacitivity, biodegradable or non-biodegradation polymer.
The kind of solvent is then depended in the preparation of solvent, and common solvent has commercially available, also can make by oneself, and as distilled water, water for injection, physiology buffer towards liquid, dehydrated alcohol or the preparation of various salt, but must be in strict accordance with related standards.Special solvent need be considered the kind of suspending agent and the medicine that composition, solvent suspended, composition, character and the requirement thereof of sustained-release micro-spheres (or microcapsule) and the preparation method of injection, as sodium carboxymethyl cellulose (1.5%)+mannitol and/or sorbitol (15%) and/or Tween 80 (0.1%) are dissolved in the normal saline mutually deserved solvent, viscosity is at 10cp-650cp (20 ℃-30 ℃ time).
The present invention finds to influence medicine and/or sustained-release micro-spheres suspends and/or the key factor of injection is the viscosity of solvent, and viscosity is big more, and suspension effect is good more, and syringeability is strong more.This unexpected one of main index characteristic of the present invention of finding to have constituted.The viscosity of solvent depends on the viscosity of suspending agent, and the viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), preferred 1000cp-3000cp (20 ℃-30 ℃ time), most preferably 1500cp-3000cp (20 ℃-30 ℃ time).According to the viscosity of the prepared solvent of this condition is 10cp-650cp (20 ℃-30 ℃ time), preferred 20cp-650cp (20 ℃-30 ℃ time), most preferably 60cp-650cp (20 ℃-30 ℃ time).
The preparation of injection has several different methods, and a kind of is that the sustained-release microparticle (A) of suspending agent for " 0 " directly mixed in special solvent, obtains corresponding sustained-release microparticle injection; Another kind is that suspending agent is not mixed in special solvent or common solvent for the sustained-release microparticle (A) of " 0 ", obtains corresponding sustained-release microparticle injection; Another is that sustained-release microparticle (A) is mixed in common solvent, adds the suspending agent mixing then, obtains corresponding sustained-release microparticle injection.Except, also can earlier sustained-release microparticle (A) be mixed and in special solvent, make corresponding suspension, with the moisture in ways such as the vacuum drying removal suspension, special solvent of reuse or common solvent suspendible obtain corresponding sustained-release microparticle injection afterwards then.Above method just is illustrative rather than definitive thereof the present invention.It should be noted that suspended drug or sustained-release micro-spheres (or microcapsule) concentration in injection decide because of specifically needing, can be, but be not limited to, 10-400mg/ml, but be preferably with 30-300mg/ml, with 50-200mg/ml most preferably.The viscosity of injection is 50cp-1000cp (20 ℃-30 ℃ time), preferred 100cp-1000cp (20 ℃-30 ℃ time), most preferably 200cp-650cp (20 ℃-30 ℃ time).This viscosity is applicable to 18-22 injection needle and special bigger (to 3 millimeters) injection needle of internal diameter.
The application of injection comprises the application of the injection of making after the application of application, solvent of sustained-release micro-spheres or drug microparticles and sustained-release micro-spheres or drug microparticles suspend in solvent.
Microsphere is used to prepare slow releasing injection, as suspension type slow releasing injection, gel injection, block copolymer micelle injection.In various injections, serve as preferred with the suspension type slow releasing injection.The suspension type slow releasing injection is to contain the medicament slow-release microsphere of effective composition or the preparation that drug microparticles is suspended in gained in the solvent, and used adjuvant is a kind of or its combination in the above-mentioned slow-release auxiliary material, and used solvent is common solvent or the special solvent that contains suspending agent.Common solvent is, but is not limited to the buffer that distilled water, water for injection, physiology are prepared towards liquid, dehydrated alcohol or various salt; Block copolymer micelle is formed in aqueous solution by hydrophobic hydrophilic block copolymers, has the spherical inner core shell mechanism, and hydrophobic block forms kernel, and hydrophilic block forms shell.The carrier micelle injection enters the purpose that reaches control drug release or targeted therapy in the body.Used pharmaceutical carrier is above-mentioned any one or its combination.Wherein preferred molecular weight is the hydrophilic block of the Polyethylene Glycol (PEG) of 1000-15000 as the micelle copolymer, and preferred biological degradation polyalcohol (as PLA, polylactide, polycaprolactone and copolymer thereof (molecular weight 1500-25000)) is as the hydrophobic block of micelle copolymer.The particle size range of block copolymer micelle can be at 1-300um, but is preferred with 20-200um, and 30-150um most preferably; Gel injection system is dissolved in some amphipathic solvent with biological degradation polyalcohol (as PLA, PLGA or DL-LA and epsilon-caprolactone copolymer), adds medicine miscible with it (or suspendible) back again and forms flowability gel preferably, can be through tumor week or intratumor injection.In case inject, amphipathic solvent diffuses to body fluid very soon, the moisture in the body fluid then infiltrates gel, makes polymer cure, slowly discharges medicine.
The application of solvent refers to that mainly the application of special solvent is effective suspension, stablizes and/or protects various medicines or sustained-release micro-spheres (or microcapsule), thereby prepares corresponding injection.The application of special solvent can make prepared injection have better injectivity, stability and higher viscosity.
The application of injection be with full-bodied special solvent with pastille microgranule, particularly sustained-release microparticle, make corresponding slow releasing injection, thus make corresponding medicine can with the injection mode import in the patient or mammalian body of required medicine.The medicine that is injected can be, but is not limited to, said medicine micropowder or medicament slow release microgranule.
The route of administration of injection depends on multiple factor.For the non-proliferative pathological changes, can be in vein, lymphatic vessel, subcutaneous, muscle, intracavity (in as abdominal cavity, thoracic cavity, articular cavity and in the canalis spinalis), tissue, tumor in, reach in the bone marrow in all, the selective arterial injection of tumor, lymph node and inject.For proliferative lesion, as the entity tumor, though can be through above-mentioned administration, with in selective arterial, intracavity, the tumor, the injection of tumor week serves as preferred.
For obtaining valid density in former or position, metastatic tumour place, also can unite and give through number of ways, in the time of as vein, lymphatic vessel, subcutaneous, muscle, intracavity (as in abdominal cavity, thoracic cavity, the articular cavity and in the canalis spinalis) or selective arterial injection in conjunction with local injection.So administering drug combinations is specially adapted to entity tumor.As in the tumor, tumor week injection time is in conjunction with systemic injection.
The present invention can be used to prepare the medicine of the various tumors for the treatment of people and animal, is mainly slow releasing injection.
Another form of anticancer medicine slow-release preparation containing of the present invention is that anticancer medicine slow-release preparation containing is a sustained-release implant.The effective ingredient of anticancer implant can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion and/or the mode of degrading through polymer.
The characteristics of sustained-release implant are that used slow-release auxiliary material removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other adjuvant.The pharmaceutic adjuvant that adds is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, blocker, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
The Main Ingredients and Appearance of sustained-release implant can be made into multiple dosage form.As, but be not limited to capsule, slow releasing agent, implant, slow releasing agent implant etc.; Be multiple shape, as, but be not limited to granule, pill, tablet, powder, granule, sphere, bulk, needle-like, bar-shaped, column and membranaceous.In various dosage forms, serve as preferred slowly to discharge implant in the body.
The most preferred dosage form of sustained-release implant is that the slow releasing agent that biocompatibility, degradable absorb is implanted, and can make different shape and various dosage form because of the clinical needs of difference.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, drying, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.
The route of administration of slow releasing agent depends on multiple factor, for obtain valid density in former or position, metastatic tumour place, medicine can give through number of ways, as in subcutaneous, intracavity (in abdominal cavity, thoracic cavity and canalis spinalis), the tumor, in all injections of tumor or placement, selective arterial injection, the lymph node and injection in the bone marrow.With in selective arterial injection, intracavity, the tumor, tumor week injection or be placed as preferred.
The present invention can be used to prepare the pharmaceutical preparation of the various tumors for the treatment of people and animal, be mainly slow releasing injection or sustained-release implant, the indication tumor comprises former or cancer or sarcoma or the carcinosarcoma that shifts that originates from brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon, rectum.
The tumor of above-mentioned internal organs can be different histological type, and why the tumor of the lymph node of lymph node divides outstanding golden lymphoma and non_hodgkin lymphoma, and pulmonary carcinoma comprises small cell lung cancer and nonsmall-cell lung cancer etc., and the cerebral tumor comprises glioma etc.Yet common tumor comprises entity tumors such as the retinoblastoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis of the cerebral tumor, cerebral glioma, renal carcinoma, hepatocarcinoma, carcinoma of gallbladder, tumor of head and neck, oral cancer, thyroid carcinoma, skin carcinoma, hemangioma, osteosarcoma, lymphoma, pulmonary carcinoma, thymic carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, eyes.
The application of sustained-release implant and the same slow-releasing anticarcinogen injection of potentiation mode, the cancer therapy drug that place the associating of the chemical-therapy synergistic agent of the associating of the cancer therapy drug of the promptly local chemical-therapy synergistic agent of placing and other administration, the local cancer therapy drug of placing and other administration, part and the associating of the local chemical-therapy synergistic agent of placing.Wherein the cancer therapy drug of topical application and chemical-therapy synergistic agent can be separately or Joint Production, packing, sale, use.Packing refers to medicine carrying process and pastille slow-release agent the exterior and interior packing for transport and/or store of medicine for adjuvant.The medicine carrying process includes, but not limited to weighing, dissolving, mixing, drying, shaping, coating, spraying, granulation etc.As medicine is mixed and made into the sustained-release micro-spheres that contains different pharmaceutical with different adjuvant, this sustained-release micro-spheres is packing and storing separately, when using simultaneously or successively be injected in the body; This sustained-release micro-spheres also can further be shaped by several different methods, makes the sustained-release implant of different shape.
The clinical practice dosage of effective ingredient depends on patient's concrete condition, can be from 0.01 to 1000mg/kg body weight, and 0.1 to 800mg/kg is preferred, 1 to 500mg/kg for there being most choosing.
The consumption of the anticancer effective component in the sustained-release implant can be with reference to slow releasing injection.But be preferably as follows:
(a) 7-hydroxy-star shaped spore native of 1-40%, 7-O-alkyl-star shaped spore native, beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate, octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate, 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine or 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine;
(b) Camptothecin of 1-40%, hydroxy-camptothecin alkali, lurtotecan, topotecan, irinotecan, etoposide, teniposide, amrubicin, Ai Rou are than star, detorubicin, amycin, epirubicin, esorubicin, carubicin, rodorubicin, leurubicin, medorubicin, Nemorubicin, zorubicin, doxorubicin, pirarubicin, valrubicin or idarubicin; Or
(c) 7-hydroxy-star shaped spore native of 1-40%, 7-O-alkyl-star shaped spore native, the beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate, octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate, 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, the Camptothecin of 1-O octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine or 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine and 1-40%, hydroxy-camptothecin alkali, lurtotecan, topotecan, irinotecan, etoposide, teniposide, amrubicin, Ai Rou compares star, detorubicin, amycin, epirubicin, esorubicin, carubicin, rodorubicin, leurubicin, medorubicin, Nemorubicin, zorubicin, doxorubicin, pirarubicin, the combination of valrubicin or idarubicin.
Also can add other medicinal ingredient in the made slow releasing injection of the present invention, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.
By following test and embodiment technical method of the present invention is further described:
The local drug concentration that test 1, different modes are used behind 7-hydroxy-star shaped spore native compares
With the rat is subjects, with 2 * 10
5Individual prostate tumor cells subcutaneous injection is in its hypochondrium, treats behind tumor growth to 1 cm diameter its grouping.Every group of dosage is 5mg/kg.Measure medicament contg (%) in the different time tumor, the result shows, the local drug concentration significant difference of 7-hydroxy-star shaped spore native after different modes is used, topical can obviously improve and effectively keep the active drug concentration at position, tumor place, and is wherein best with the effect of placing sustained-release implant and intratumor injection slow releasing injection in the tumor.Yet, intratumor injection slow releasing injection operation most convenient, easy.This discovery constitutes key character of the present invention.Following relevant inhibition test has further confirmed this point.
The interior tumor-inhibiting action of body that test 2, different modes are used behind 7-O-alkyl-star shaped spore native compares
With the rat is subjects, with 2 * 10
5Individual breast tumor cell subcutaneous injection is in its hypochondrium, treats behind tumor growth to 0.5 cm diameter its grouping.Every group of dosage is 15mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect on the 20th day.The result shows, the tumor-inhibiting action significant difference of 7-O-alkyl-star shaped spore native after different modes is used, topical can obviously improve and effectively keep the active drug concentration at position, tumor place, and is wherein best with the effect of placing sustained-release implant and intratumor injection slow releasing injection in the tumor.Yet, intratumor injection slow releasing injection operation most convenient, easy.Good effect not only, toxic and side effects is also little.
Test 3, contain the tumor-inhibiting action of hexa-decyl choline phosphate and topoenzyme inhibitor
With the rat is subjects, with 2 * 10
5Individual pancreatic tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it matched group and treatment group (1-11).The treatment component is hexa-decyl choline phosphate group, topoenzyme inhibitor group, hexa-decyl choline phosphate and topoenzyme inhibitor group.Hexa-decyl choline phosphate group and topoenzyme inhibitor drug dose are respectively 25mg/kg and 5mg/kg, through intratumor injection.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 1) on the 20th day.
Table 1
| Group | UCN-1 | Synergist | Tumor control rate (%) | The P value |
| 1 | + | - | 64 | * |
| 2 | - | Camptothecine | 46 | * |
| 3 | - | Hydroxy camptothecin | 42 | * |
| 4 | - | Lurtotecan | 38 | * |
| 5 | - | Topotecan | 48 | * |
| 6 | - | Irinotecan | 36 | * |
| 7 | + | Camptothecine | 86 | ** |
| 8 | + | Hydroxy camptothecin | 82 | ** |
| 9 | + | Lurtotecan | 88 | ** |
| 10 | + | Topotecan | 86 | ** |
| 11 | + | Irinotecan | 82 | ** |
Above result shows, phosphoinositide 3 inhibitors of kinases (hexa-decyl choline phosphate) and used topoenzyme inhibitor (Camptothecin, hydroxy-camptothecin alkali, lurtotecan, topotecan, irinotecan) all have significant inhibitory effect (*: the P value is less than 0.05) to tumor growth when this concentration is used separately, can show the potentiation (* *: the P value is less than 0.001) of highly significant when use in conjunction.
The tumor-inhibiting action of test 4, UCN-1 and topoenzyme inhibitor (slow releasing injection)
Used tumor cell comprises CNS-1, C6, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT) etc.UCN-1 and topoenzyme inhibitor are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its growth of tumour cell suppresses effect (%) and is shown in Table 2.
Table 2
| Oncocyte | PI3Ki | A | B | C | D | E | PI3Ki+A | PI3Ki+B | PI3Ki+C | PI3Ki+D | PI3Ki+E |
| CNS | 52 | 50 | 48 | 38 | 58 | 42 | 88 | 88 | 82 | 78 | 88 |
| C6 | 54 | 52 | 46 | 36 | 64 | 40 | 90 | 80 | 84 | 84 | 90 |
| SA | 52 | 58 | 36 | 42 | 62 | 48 | 88 | 84 | 86 | 82 | 82 |
| BC | 58 | 54 | 40 | 42 | 64 | 54 | 88 | 80 | 74 | 74 | 80 |
| BA | 68 | 46 | 38 | 48 | 60 | 56 | 80 | 80 | 92 | 92 | 80 |
| LH | 66 | 56 | 40 | 52 | 58 | 60 | 90 | 82 | 94 | 78 | 94 |
| PAT | 60 | 48 | 46 | 50 | 54 | 68 | 82 | 76 | 82 | 80 | 80 |
Above result shows, used PI3Ki (UCN-1) and topoenzyme inhibitor (A wherein: etoposide, B: teniposide, C: amrubicin, D: Ai Rou compares star, E: detorubicin) growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 5, UCN-2 and topoenzyme inhibitor (slow releasing injection)
Used tumor cell comprises CNS-1, C6,9L, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT), hepatocarcinoma etc.UCN-2 and topoenzyme inhibitor are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its growth of tumour cell suppresses effect and shows, growth all has obvious suppression effect (P＜0.05) to kinds of tumor cells when using separately for used UCN-2 and topoenzyme inhibitor (detorubicin, amycin, epirubicin, esorubicin, carubicin), can show significant potentiation (P＜0.01) when use in conjunction.
Test 6, contain the tumor-inhibiting action of PI3Ki and topoenzyme inhibitor
With the rat is subjects, with 2 * 10
5Individual pancreatic tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it matched group and treatment group (1-11).The treatment component is PI3Ki group, topoenzyme inhibitor group, PI3Ki and topoenzyme inhibitor group.PI3Ki group and topoenzyme inhibitor drug dose are respectively 25mg/kg and 5mg/kg, through intratumor injection.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 3) on the 20th day.
Table 3
| Group | PI3Ki | Synergist | Tumor control rate (%) | The P value |
| 1 | + | - | 60 | * |
| 2 | - | Camptothecine | 46 | * |
| 3 | - | Hydroxy camptothecin | 42 | * |
| 4 | - | Lurtotecan | 38 | * |
| 5 | - | Topotecan | 48 | * |
| 6 | - | Irinotecan | 36 | * |
| 7 | + | Camptothecine | 78 | ** |
| 8 | + | Hydroxy camptothecin | 72 | ** |
| 9 | + | Lurtotecan | 78 | ** |
| 10 | + | Topotecan | 82 | ** |
| 11 | + | Irinotecan | 86 | ** |
Above result shows, PI3Ki (Perifosine) and used topoenzyme inhibitor (camptothecine, hydroxy camptothecin, lurtotecan, topotecan, irinotecan) all have significant inhibitory effect (*: the P value is less than 0.05) to tumor growth when this concentration is used separately, can show the potentiation (* *: the P value is less than 0.001) of highly significant when use in conjunction.
The tumor-inhibiting action of test 7, PI3Ki and topoenzyme inhibitor (slow releasing injection)
Used tumor cell comprises CNS-1, C6, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT) etc.PI3Ki and topoenzyme inhibitor are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its growth of tumour cell suppresses effect (%) and is shown in Table 4.
Table 4
| Oncocyte | UCN-2 | A | B | C | D | E | UCN-2+A | UCN-2+B | UCN-2+C | UCN-2+D | UCN-2+E |
| CNS | 22 | 50 | 48 | 38 | 58 | 42 | 88 | 84 | 82 | 78 | 82 |
| C6 | 34 | 52 | 46 | 36 | 64 | 40 | 90 | 80 | 84 | 84 | 80 |
| SA | 52 | 58 | 36 | 42 | 62 | 48 | 88 | 84 | 86 | 82 | 82 |
| BC | 58 | 54 | 40 | 42 | 64 | 54 | 88 | 80 | 74 | 74 | 80 |
| BA | 58 | 46 | 38 | 48 | 60 | 56 | 80 | 80 | 92 | 92 | 80 |
| LH | 46 | 56 | 40 | 52 | 58 | 60 | 90 | 82 | 84 | 78 | 74 |
| PAT | 40 | 48 | 46 | 50 | 54 | 78 | 82 | 76 | 82 | 80 | 80 |
Above result shows that used topoenzyme inhibitor is A: detorubicin, B: amycin, C: epirubicin, D: esorubicin, E: carubicin.Growth all has the obvious suppression effect to said medicine to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 8, Edelfosine and topoenzyme inhibitor (slow releasing injection)
Used tumor cell comprises CNS-1, C6,9L, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT), hepatocarcinoma etc.Edelfosine and topoenzyme inhibitor are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its growth of tumour cell suppresses effect and shows, growth all has obvious suppression effect (P＜0.05) to kinds of tumor cells when using separately for used Edelfosine and topoenzyme inhibitor (rodorubicin, leurubicin, medorubicin, Nemorubicin, zorubicin, doxorubicin, pirarubicin, valrubicin or idarubicin), can show significant potentiation (P＜0.01) when use in conjunction.
The above results shows that when use in conjunction, the weight ratio of PI3Ki and topoenzyme inhibitor is 1-9: 1 to 1: 1-9, with 1-4: 1 and 4-1: 1 serves as preferred, 1-2: 1 and 2-1: 1 for most preferably.
Studies show that further topoenzyme inhibitor such as hydroxy camptothecin, lurtotecan, rodorubicin, leurubicin, medorubicin, Nemorubicin, zorubicin, doxorubicin, pirarubicin, valrubicin, idarubicin and UCN-1 or UCN-2 share tumors such as cervix uteri tumor, thyroid carcinoma, straight colon cancer, ovarian cancer and have obvious synergistic effect (P＜0.05) equally.
In a word, growth all had the obvious suppression effect to kinds of tumor cells when used PI3Ki and/or various topoenzyme inhibitor were used separately, can show significant potentiation when use in conjunction.Therefore, effective ingredient of the present invention is the combination of any one PI3Ki and/or any one topoenzyme inhibitor.The medicine that contains above effective ingredient can be made into sustained-release micro-spheres, and then makes slow releasing injection and implant, serves as preferred with the suspensoid injectio that is combined to form with the special solvent that contains suspending agent wherein.
Slow releasing injection or sustained-release implant also can be further specified by following embodiment.Just the invention will be further described for the foregoing description and following examples, is not its content and use are imposed any restrictions.
(4) specific embodiment
Embodiment 1.
With 80,80 and 80mg p (BHET-EOP/TC) (BHET-EOP: TC is 80: 20) copolymer put into first, second and the third three containers respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, add 20mgUCN-1,20mg irinotecan, 10mgUCN-1 and 10mg irinotecan respectively, shake up the back again and contain 20%UCN-1,20% irinotecan, and the injectable microsphere of 10%UCN-1 and 10% irinotecan with spray drying method for preparation.Then microsphere is suspended in the normal saline that contains 15% mannitol, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 40-50 days, is more than 50 days at the drug release time of the subcutaneous hepatocarcinoma of mice.
Embodiment 2.
The method step that is processed into slow releasing injection is identical with embodiment 1, but different is that used adjuvant is 50: 50 p (BHET-EOP/TC), contains anticancer effective component and percentage by weight thereof and is:
(1) UCN-1 of 1-40% or UCN-2;
(2) Camptothecin of 1-40%, hydroxy-camptothecin alkali, lurtotecan, topotecan, irinotecan, etoposide, teniposide, amrubicin, Ai Rou are than star, detorubicin, amycin, epirubicin, esorubicin, carubicin, rodorubicin, leurubicin, medorubicin, Nemorubicin, zorubicin, doxorubicin, pirarubicin, valrubicin or idarubicin; Or
(3) Camptothecin of the UCN-1 of 1-40% or UCN-2 and 1-30%, hydroxy-camptothecin alkali, lurtotecan, topotecan, irinotecan, etoposide, teniposide, amrubicin, Ai Rou are than the combination of star, detorubicin, amycin, epirubicin, esorubicin, carubicin, rodorubicin, leurubicin, medorubicin, Nemorubicin, zorubicin, doxorubicin, pirarubicin, valrubicin or idarubicin.
Embodiment 3.
With 70mg molecular weight peak value is that the p (LAEG-EOP) of 10000-25000 puts into first, second and the third three containers respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, in three containers, add 30mgUCN-2,30mg irinotecan, 20mgUCN-2 and 10mg irinotecan respectively, shake up the back contains 30%UCN-2,30% irinotecan, 20%UCN-2 and 10% irinotecan with spray drying method for preparation injectable microsphere again.Dried microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 55-65 days, is about 60 days at the drug release time of mice lung cancer.
Embodiment 4
The method step that is processed into slow releasing injection is identical with embodiment 3, but the molecular weight peak value of different is p (LAEG-EOP) is 25000-45000, and contained anticancer effective component and percentage by weight thereof are:
(1) irinotecan of 5-30%, hydroxy camptothecin or lurtotecan; Or
(2) UCN-1 of 5-40% or UCN-2; Or
(3) combination of the irinotecan of the UCN-1 of 5-30% or UCN-2 and 5-30%, hydroxy camptothecin or lurtotecan.
Embodiment 5.
With 60mg molecular weight peak value is that the p (DAPG-EOP) of 10000-25000 puts into container, after adding 100 milliliters of dichloromethane dissolving mixings, add 30 milligrams of UCN-1 and 10 milligrams of lurtotecan, shake up the back contains 30%UCN-1 and 10% lurtotecan with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the injection that contains 15% sorbitol, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 50-55 days, is about 55 days at the drug release time of the subcutaneous gastric cancer of mice.
Embodiment 6.
The method step that is processed into slow releasing injection is identical with embodiment 5, but the molecular weight peak value of different is used adjuvant is 25000-45000, contains anticancer effective component and is:
(1) UCN-1 of 5-40%; Or
(2) lurtotecan of 1-20%; Or
(3) combination of the lurtotecan of the UCN-1 of 5-30% and 1-20%.
Embodiment 7.
With 70mg molecular weight peak value is the p (BHDPT-EOP/TC of 10000-25000,80/20) puts into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 25mgPerifosine and 5mg topotecan, shake up the back contains 25%Perifosine and 5% topotecan with spray drying method for preparation injectable microsphere again.Microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 0.5% Tween 80 then, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 40-45 days, is about 50 days at the drug release time of the subcutaneous esophageal carcinoma of mice.
Embodiment 8.
The method step that is processed into slow releasing injection is identical with embodiment 7, but the molecular weight peak value of different is p (BHDPT-EOP/TC) is 40000-65000, and BHDPT-EOP: TC is 50: 50, and contained anticancer effective component is:
(1) topotecan of 10-20%;
(2) UCN-1 of 10-25% or Perifosine; Or
(3) combination of the UCN-1 of the topotecan of 10-20% and 10-25% or Perifosine.
Embodiment 9.
With 30mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) and 40mg molecular weight peak value is that p (DAPG-EOP) copolymer of 30000-45000 is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 30mgEdelfosine, 30mg amycin, 5mgEdelfosine and 25mg amycin respectively, shake up the back again and contain 30%Edelfosine, 30% amycin, 5%Edelfosine and 25% amycin injectable microsphere with spray drying method for preparation.Then microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 15% sorbitol and 0.2% Tween 80, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 40-45 days, is about 45 days at the drug release time of mice skin rectal cancer.
Embodiment 10.
The method step that is processed into slow releasing injection is identical with embodiment 9, but different is in the polifeprosan to carboxy phenyl propane: the certain herbaceous plants with big flowers diacid is 50: 50, and the molecular weight peak value of p (DAPG-EOP) is 40000-65000, and contained anticancer effective component is:
(1) UCN-1 of 5-30%;
(2) amycin of 20-40%;
(3) combination of the amycin of the UCN-1 of 5-20% and 10-40% or epirubicin.
Embodiment 11
With 40mg molecular weight peak value is that (LAEG-EOP) of 20000-45000p and PLA copolymer that 30mg molecular weight peak value is 10000-25000 are put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg hydroxy camptothecin and 20mgIlmofosine, shake up the back contains 10% hydroxy camptothecin and 20%Ilmofosine with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 40-45 days, is about 45 days at the drug release time of the subcutaneous breast carcinoma of mice.
Embodiment 12
The method step that is processed into sustained-release implant is identical with embodiment 11, but different is used adjuvant contains anticancer effective component to be for the molecular weight peak value is that (LAEG-EOP) and the molecular weight peak value of 40000-65000p is the PLA of 25000-45000:
(1) hydroxy camptothecin of 10-20%; Or
(2) Ilmofosine of 10-20%; Or
(3) combination of the Ilmofosine of the camptothecine of 10-20% or hydroxy camptothecin and 10-20%.
Embodiment 13
With 40mg molecular weight peak value is the polylactic acid (PLGA of 15000-35000,50: 50) and 30 molecular weight peak values be that (LAEG-EOP) of 20000-45000p puts into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg irinotecan and 20mgMilefosine, shake up the back contains 10% irinotecan and 20%Milefosine with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 50-60 days, is about 60 days at the drug release time of the subcutaneous cancer of pancreas of mice.
Embodiment 14
The method step of processing sustained-release implant is identical with embodiment 11,13, but different is that contained anticancer effective component is:
(1) UCN-1 of 10-20% or Milefosine; Or
(2) irinotecan of 10-20%, hydroxy camptothecin or lurtotecan; Or
(3) combination of the irinotecan of the UCN-1 of 10-20% or Milefosine and 10-20%, hydroxy camptothecin or lurtotecan.
Embodiment 15
The method step that is processed into slow releasing agent is identical with embodiment 1-14, but different is used slow-release auxiliary material is one of following or its combination:
A) p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP);
B) p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP) are the combination of the polyglycolic acid of 10000-30000,30000-60000,60000-100000 or 100000-150000 and the copolymer of hydroxyacetic acid (PLGA) with the molecular weight peak value, wherein, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50;
C) p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP) and of the combination of molecular weight peak value for the polylactic acid (PLA) of 10000-30000,30000-60000,60000-100000 or 100000-150000;
D) combination of p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP) and polifeprosan, wherein in the polifeprosan to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40;
E) p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP) and bis-fatty acid and decanedioic acid copolymer (PFAD-SA)], poly-(erucic acid dimer decanedioic acid) [P (EAD-SA)], poly-(fumaric acid decanedioic acid) [P (FA-SA)], xylitol, oligosaccharide, chrondroitin, chitin, chitosan, poloxamer, hyaluronic acid, collagen protein, the combination of gelatin or white tempera.
Embodiment 16.
The method step that is processed into slow releasing injection is identical with embodiment 1-15, but different is used suspending agent is respectively one of following or its combination:
A) 0.5-3.0% carboxymethyl cellulose (sodium);
B) 5-15% mannitol;
C) 5-15% sorbitol;
D) 0.1-1.5% surfactant;
E) 0.1-0.5% polysorbas20.
Embodiment 17
The method step of processing sustained-release implant is identical with embodiment 11,13, but different is that contained anticancer effective component is:
(1) camptothecine of 1-40%, hydroxy camptothecin, irinotecan, lurtotecan, etoposide, teniposide, amycin, topotecan or epirubicin; Or
(2) 7-hydroxy-star shaped spore native of 1-40%, 7-O-alkyl-star shaped spore native, beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate, octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate, 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine or 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine; Or
(3) 7-hydroxy-star shaped spore native of 20-40%, 7-O-alkyl-star shaped spore native, the beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate, octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate, 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, the camptothecine of 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine or 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine and 1-20%, hydroxy camptothecin, irinotecan, lurtotecan, etoposide, teniposide, amycin, the combination of epirubicin or topotecan; Or
(4) combination of hydroxy camptothecin, irinotecan, lurtotecan, amycin, epirubicin or the topotecan of 7-hydroxy-star shaped spore native of 1-20%, 7-O-alkyl star shaped spore native, beta-methoxy-star shaped spore native, alkyl phosphate choline, hexa-decyl choline phosphate, octadecyl-(1, the 1-dimethyl-4-piperidine) phosphate, 1-O-six decyls-2-O-methyl-rac-glyceryl-3-phosphocholine, 1-O-octadecyl-2-O-methyl-rac-glyceryl-3-phosphocholine or 1-O-octadecyl-2-O-methyl-sn-glyceryl-3-phosphocholine and 20-40%.
Drug release characteristic (table 5) after embodiment 18 more different slow-release auxiliary material and the combination thereof
The method step of processing sustained-release implant is identical with embodiment 11, the drug release characteristic after more different slow-release auxiliary material and the combination thereof.First day release amount of medicine (external) surpass 20% of total amount and release for prominent.
Table 5
| Slow-release auxiliary material | Molecular weight | Medicine and content | Drug release time (my god) | Not prominent releasing arranged |
| (1) PLA (2) PLGA (50/50) (3) polifeprosan (20/80) (4) p (LAEG-EOP) (1): (4)=1: 1 (2): (4)=1: 1 (3): (4)=1: 1 (5) PLA (6) PLGA (75/25) (7) polifeprosan (50/50) (8) p (DAPG-EOP) (5): (8)=6: 4 (6): (8)=7: 3 (7): (8)=5: 5 | 10000-25000 20000-40000 20000-40000 15000-35000 25000-45000 10000-20000 10000-20000 35000-55000 | UCN-1 (20%) UCN-1 (20%) UCN-1 (20%) UCN-1 (20%) UCN-1 (20%) UCN-1 (20%) UCN-1 (20%) camptothecine (20%) camptothecine (20%) camptothecine (20%) camptothecine (20%) camptothecine (20%) camptothecine (20%) camptothecine (20%) | 22 28 10 48 42 44 42 26 25 10 54 50 48 46 | Not having to have or not have to have or not does not have |
Data show in the table, and when PLA, PLGA (50/50) and polifeprosan sugared acid anhydride family macromolecule polymer such as (20/80) were used separately, drug release was very fast, and wherein the drug release time of polifeprosan is 8-10 days and obviously prominent releasing arranged.P (LAEG-EOP) and p poly phosphate high molecular polymer releases such as (DAPG-EOP) are slow and steady, can alleviate caused prominent the releasing of the latter when share with sugared acid anhydride family macromolecule polymer such as PLA, PLGA, polifeprosans, but its steadily slowly drug release feature be not subjected to too big influence.This beyond thought discovery constitutes another major technique feature of the present invention.Because the poly phosphate high molecular polymer costs an arm and a leg, this will help reducing the cost of slow releasing preparation, and improve its drug release feature.
Drug release characteristic (table 6) after embodiment 19 more different slow-release auxiliary material and the combination thereof
The method step of processing sustained-release implant is identical with embodiment 11, the drug release characteristic after more different slow-release auxiliary material and the combination thereof.First day release amount of medicine (external) surpass 20% of total amount and release for prominent.
Table 6
| Slow-release auxiliary material | Molecular weight | Medicine and content | Drug release time (my god) | Not prominent releasing arranged |
| (1) PLA (2) PLGA (50/50) (3) polifeprosan (20/80) (4) p (LAEG-EOP) (1): (4)=1: 1 (2): (4)=1: 1 (3): (4)=1: 1 (5) PLA (6) PLGA (75/25) (7) polifeprosan (50/50) (8) p (DAPG-EOP) (5): (8)=6: 4 (6): (8)=7: 3 (7): (8)=5: 5 | 20000-35000 30000-45000 20000-40000 25000-45000 25000-45000 20000-40000 20000-40000 35000-55000 | UCN-2 (20%) UCN-2 (20%) UCN-2 (20%) UCN-2 (20%) UCN-2 (20%) UCN-2 (20%) UCN-2 (20%) irinotecan (10%) irinotecan (10%) irinotecan (10%) irinotecan (10%) irinotecan (10%) irinotecan (10%) irinotecan (10%) | 25 32 11 48 43 45 42 27 25 13 57 55 52 50 | Not having to have or not have to have or not does not have |
Data show in the table, and when PLA, PLGA (50/50) and polifeprosan sugared acid anhydride family macromolecule polymer such as (20/80) were used separately, drug release was very fast, and wherein the drug release time of polifeprosan is 10-13 days and obviously prominent releasing arranged.P (LAEG-EOP) and p poly phosphate high molecular polymer releases such as (DAPG-EOP) are slow and steady, can alleviate caused prominent the releasing of the latter when share with sugared acid anhydride family macromolecule polymer such as PLA, PLGA, polifeprosans, but its steadily slowly drug release feature be not subjected to too big influence.This beyond thought discovery constitutes another major technique feature of the present invention.Because the poly phosphate high molecular polymer costs an arm and a leg, this will help reducing the cost of slow releasing preparation, and improve its drug release feature.
This release rule also sees to the other drug combination, as the combination of topotecan and UCN-1 and the combination of hydroxy camptothecin or etoposide and UCN-2.
Above embodiment only is used for explanation, and is not limitation application of the present invention.
The present invention disclosed and the protection the content see claim.
Claims (3)
1. the anti-cancer composition of including phosphatidylinositol3 3-kinase inhibitor and topoenzyme inhibitor is characterized in that anti-cancer composition is a slow releasing injection, is grouped into by following one-tenth:
Anticancer effective component is 20%UCN-2 and 10% irinotecan, and slow-release auxiliary material is that 70% molecular weight peak value is the p (LAEG-EOP) of 10000-25000, and solvent is the normal saline that contains 1.5% sodium carboxymethyl cellulose.
2. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that effective ingredient in the slow-releasing anticarcinogen injection is used to prepare the pharmaceutical preparation that treatment originates from cancer, sarcoma or the carcinosarcoma of people and animal brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon or rectum former or secondary.
3. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that slow-releasing anticarcinogen injection in tumor or tumor week injection or place administration, in sustained release profile in vivo test more than 40 days.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810303544XA CN101332199A (en) | 2007-03-23 | 2007-03-23 | Anticancer composition containing phosphoinositide 3-kinase inhibitor and topology enzyme inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810303544XA CN101332199A (en) | 2007-03-23 | 2007-03-23 | Anticancer composition containing phosphoinositide 3-kinase inhibitor and topology enzyme inhibitor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007102003220A Division CN101019830A (en) | 2007-03-23 | 2007-03-23 | Anticancer composition containing phosphoinositide-3-kinase inhibitor and topomerase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101332199A true CN101332199A (en) | 2008-12-31 |
Family
ID=40195254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200810303544XA Pending CN101332199A (en) | 2007-03-23 | 2007-03-23 | Anticancer composition containing phosphoinositide 3-kinase inhibitor and topology enzyme inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101332199A (en) |
-
2007
- 2007-03-23 CN CNA200810303544XA patent/CN101332199A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1961864A (en) | Anticancer composition | |
| CN101433520A (en) | Anticancer sustained-release agent containing epothilone | |
| CN101084876A (en) | Anti-cancer composition containing bendamustine | |
| CN101011341A (en) | Slow release injection containing anti-metabolism medicament and topoisomerase inhibitor | |
| CN101380303A (en) | Anti-cancer medicine sustained-released injection loaded with platinum compound and synergist thereof | |
| CN101444482A (en) | Sustained-release injection containing nitrosourea drugs | |
| CN101020057A (en) | Composition for treating solid tumor | |
| CN101332199A (en) | Anticancer composition containing phosphoinositide 3-kinase inhibitor and topology enzyme inhibitor | |
| CN101332204A (en) | Anticancer composition containing phosphoinositide 3-kinase inhibitor and topology enzyme inhibitor | |
| CN101332201A (en) | Anticancer composition containing irinotecan | |
| CN101332179A (en) | Anticancer composition containing lurtotecan | |
| CN101332181A (en) | Anticancer composition containing irinotecan | |
| CN101390865A (en) | Anticancer composition containing lurtolecan | |
| CN101019830A (en) | Anticancer composition containing phosphoinositide-3-kinase inhibitor and topomerase inhibitor | |
| CN101084877A (en) | Anti-cancer composition containing fotemustine | |
| CN100531716C (en) | Slow-released injection containing methotrexate and its synergist | |
| CN101336893A (en) | Sustained-released injection containing bortezomib and topology enzyme inhibitor | |
| CN100998868A (en) | Antientity tumour composition | |
| CN101006979A (en) | Anticancer composition containing taxane and topoenzyme inhibitor | |
| CN101011349A (en) | Slow release injection containing mtrosourea medicament and topoisomerase inhibitor | |
| CN101385709A (en) | Sustained-released injection containing carmustine of nitrosourea medicine | |
| CN101385699A (en) | Sustained-released injection containing nitrosourea medicine | |
| CN101396338A (en) | Sustained-release injection containing methotrexate and synergist thereof | |
| CN101385708A (en) | Anti-cancer sustained-released agent containing fotemustine of nitrosourea medicine | |
| CN101011347A (en) | Slow release injection containing platinum compound and topoisomerase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20081231 |